In a recent study published in the Proceedings of the National Academy of Sciences, researchers assessed the impact of an anti-CD3 monoclonal antibody (mAb) called Foralumab in coronavirus disease ...
Members of Tiziana's senior management team will also attend the forum and be available for one-on-one meetings with investors, partners, and other stakeholders. The 9th Annual Neuroscience Innovation ...
GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...
ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi's tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback